Gallium Oxodotreotide

Summary

Gallium Oxodotreotide (CHEMBL262135) is an approved protein.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Chemistry: 1502.3 Da · C65H87GaN14O19S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL262135
Name	Gallium Oxodotreotide
Type	Protein
Max phase	4
FDA approved	no
PubChem CID	44400135
Molecular formula	C65H87GaN14O19S2
Molecular weight	1502.3
InChIKey	XBJPSVQFCQFGDC-UZOALHFESA-K

SMILES: C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[Ga+3]

IUPAC name: gallium 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate

Also known as: Radiolabeled octreotide derivative

Parent form; salt/anhydrous children: CHEMBL4297340

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Somatostatin receptor type 5, Somatostatin receptor type 2, Somatostatin receptor type 4.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SSTR2	9.7	IC50	0.2	nM	CHEMBL_ACT_1503595
SSTR4	6.52	IC50	300	nM	CHEMBL_ACT_1503597
SSTR5	6.42	IC50	377	nM	CHEMBL_ACT_1503598

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).